CANAMICINE SULPHATE 1%
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
100 g of ophthalmic ointment contain 1 g of kanamycin as kanamycin monosulphate.
3. PHARMACEUTICAL FORM
Ophthalmic ointment
4. CLINICAL DATA
4.1 Therapeutic indications
Treatment of external infections of the eyeball and appendages produced by germs sensitive to kanamycin: conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcer, blepharitis, blepharoconjunctivitis, dacryocystitis.
Prophylaxis of ophthalmic surgical infections.
4.2 Posology and method of administration
KANAMICINE SULPHATE 1%, ophthalmic ointment: apply in the conjunctival sac 3-4 times a day.
4.3 Contraindications
Hypersensitivity to kanamycin or to any of the excipients.
4.4 Special warnings and precautions for use
Prolonged local use of antibiotics may increase the resistance of microorganisms.
If no significant therapeutic results have been obtained after a relatively short period of time or if hypersensitivity reactions occur, discontinuation of treatment and re-evaluation of the treatment should be discontinued.
In children, the product should be used only if absolutely necessary and under close medical supervision.
4.5 Interaction with other medicinal products and other forms of interaction
Combination with other concomitant aminoglycosides is contraindicated. It is recommended to avoid the combination of aminoglycosides, even locally, with polymyxin, cephalothin, furosemide, ethacrynic acid, amphotericin B, cyclosporine, cisplatin or other drugs with nephrotoxic and ototoxic potential (increases the risk of oto- and nephrotoxicity).
Aminoglycoside antibiotics should not be mixed with other medicines, especially beta-lactam antibiotics (in vitro studies have shown that they are mutually inactivated).
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
100 g of ophthalmic ointment contain 1 g of kanamycin as kanamycin monosulphate.
3. PHARMACEUTICAL FORM
Ophthalmic ointment
4. CLINICAL DATA
4.1 Therapeutic indications
Treatment of external infections of the eyeball and appendages produced by germs sensitive to kanamycin: conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcer, blepharitis, blepharoconjunctivitis, dacryocystitis.
Prophylaxis of ophthalmic surgical infections.
4.2 Posology and method of administration
KANAMICINE SULPHATE 1%, ophthalmic ointment: apply in the conjunctival sac 3-4 times a day.
4.3 Contraindications
Hypersensitivity to kanamycin or to any of the excipients.
4.4 Special warnings and precautions for use
Prolonged local use of antibiotics may increase the resistance of microorganisms.
If no significant therapeutic results have been obtained after a relatively short period of time or if hypersensitivity reactions occur, discontinuation of treatment and re-evaluation of the treatment should be discontinued.
In children, the product should be used only if absolutely necessary and under close medical supervision.
4.5 Interaction with other medicinal products and other forms of interaction
Combination with other concomitant aminoglycosides is contraindicated. It is recommended to avoid the combination of aminoglycosides, even locally, with polymyxin, cephalothin, furosemide, ethacrynic acid, amphotericin B, cyclosporine, cisplatin or other drugs with nephrotoxic and ototoxic potential (increases the risk of oto- and nephrotoxicity).
Aminoglycoside antibiotics should not be mixed with other medicines, especially beta-lactam antibiotics (in vitro studies have shown that they are mutually inactivated).